Author | Paul G. Richardson, MD | OncLive

Author | Paul G. Richardson, MD

Articles

Dr. Richardson on First-In-Human Phase 1 Trial With CC-92480 in R/R Myeloma

June 23, 2020

Video

Paul G. Richardson, MD, discusses the patient population analyzed in the first-in-human phase 1 trial of the CELMoD CC-92480.

Dr. Richardson on the Mechanism of Action of CC-92480 in Multiple Myeloma

June 04, 2020

Video

Paul G. Richardson, MD, discusses the mechanism of action of CC-92480 in patients with multiple myeloma.

Dr. Richardson on Phase 1 Data With CC-92480 in Multiple Myeloma

June 02, 2020

Video

Paul G. Richardson, MD, discusses phase 1 data (NCT03374085) with CC-92480 in multiple myeloma.

Dr. Richardson on the FDA Approval of Isatuximab in Relapsed/Refractory Myeloma

March 03, 2020

Video

Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses the FDA approval of isatuximab-irfc (Sarclisa) for use in combination with pomalidomide (Pomalyst) and dexamethasone in relapsed/refractory multiple myeloma.

x